Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant:...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Optimal antithrombotic therapy for patients with coexisting atrial fibrillation and stable coronary artery disease remains unclear.
• Current practice often involves adding a single antiplatelet agent to oral anticoagulation.

Purpose of the Study:

• To investigate the effectiveness and safety of adding antiplatelet therapy to vitamin K antagonist (VKA) in patients with atrial fibrillation and stable coronary artery disease.

Main Methods:

• Retrospective analysis of 8700 patients with atrial fibrillation and stable coronary artery disease (defined as 12 months post-acute coronary event) between 2002 and 2011.
• Examined risks of cardiovascular and serious bleeding events using adjusted Cox regression models based on antithrombotic therapy (VKA monotherapy, VKA + aspirin, VKA + clopidogrel).

Main Results:

• During a mean follow-up of 3.3 years, adding aspirin or clopidogrel to VKA showed similar risks of myocardial infarction/coronary death compared to VKA monotherapy.
• Thromboembolism risk was comparable across all VKA-inclusive regimens.
• Significant increases in bleeding risk were observed when aspirin (HR 1.50) or clopidogrel (HR 1.84) was added to VKA.

Conclusions:

• Adding antiplatelet therapy to VKA in atrial fibrillation patients with stable coronary artery disease does not reduce recurrent coronary events or thromboembolism.
• This combination therapy significantly increases the risk of serious bleeding.
• The current clinical practice of adding antiplatelet therapy to VKA in this patient population warrants reassessment.